Teva Pharmaceutical Industries Limited

TEVA

US8816242098

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-05-23 pm EDT			5-day change	1st Jan Change
16.76 ^USD	-0.71%		+2.82%	+60.54%

May. 17	Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	MT
May. 15	Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	MT

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024

May 08, 2024 at 07:00 am EDT

Teva Pharmaceutical Industries Limited reaffirmed earnings guidance for the full year 2024. For the year, the company expects Revenues of $15.7 - $16.3 billion.

Latest news about Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	May. 17	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	May. 15	MT
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024	May. 15	CI
Transcript : Teva Pharmaceutical Industries Limited Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM	May. 14
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	May. 13	MT
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	May. 08	MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	May. 08	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08	MT
Sector Update: Health Care	May. 08	MT
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	May. 08	MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 Revenue $3.82B	May. 08	MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 EPS $0.48	May. 08	MT
Transcript : Teva Pharmaceutical Industries Limited, Q1 2024 Earnings Call, May 08, 2024	May. 08
Teva Pharm Q1 profit falls short of estimates, revenue gains	May. 08	RE
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Teva Pharmaceutical Industries Limited Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024	May. 08	CI
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	May. 08	CI
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30	MT
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	Apr. 22	MT

Chart Teva Pharmaceutical Industries Limited

Duration

Period

Chart Teva Pharmaceutical Industries Limited

More charts

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Sector

Pharmaceuticals

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT

More Strategies

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.76 USD

Average target price

17.54 USD

Spread / Average Target

+4.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	+60.54%	19.12B
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals